“Increasing Focus on Gene Therapy for Epidermolysis Bullosa Treatment”
A significant trend driving growth in the epidermolysis bullosa (EB) market is the increasing focus on gene therapy as a treatment option. EB is a group of rare genetic disorders causing fragile skin and blistering, and researchers are exploring gene-editing techniques to correct the mutations causing the disease. For instance, companies such as Krystal Biotech are advancing gene therapy treatments, such as their ongoing clinical trials for Krystal-EB, a topical gene therapy for dystrophic EB. This approach targets the genetic root of the disease, offering potential for long-term solutions, rather than just symptom management. As gene therapy continues to show promising results, it is expected to propel market growth significantly.
